The cancer has become the second leading cause of death in China only after cardiovascular disease. The world health organization lists the United States and China as two cancer-prone countries. Although the international pharmaceutical industry has developed hundreds of anti-cancer drugs, the cancer has so far been considered as a difficult-cure and high-mortality disease.
Since the 1960s, domestic and international pharmaceutical researchers has listed the development of the vinblastine series, taxol, camptothecin series, podophyllotoxin class Harringtonine alkali extract brucea matter, coix seed extract, Curcuma extracts, including more plant sources of anti-cancer drugs. Overall rise of the new plant anticancer drug eclipsed traditional chemotherapy drugs. According to statistics, sales of plant extracts anti-cancer medicines accounted for half of the international anti-cancer drug market, and are still growing.
In all kinds of plant anti-cancer drugs, paclitaxel is particularly remarkable. Paclitaxel targeting specific cancer cells tubulin mitosis, had no effect on normal cells, but also for advanced ovarian cancer, how Jenkins disease, Kaposi's sarcoma and advanced non-small cell lung cancer and other malignancies have a certain effect, it is listed since 1992, quickly swept the world, so far has sold nearly $ 30 billion, and create a new record of the chemotherapy drugs.
The success of the anticancer drug paclitaxel as the representative of plants has greatly stimulated the enthusiasm of the World medicine academic development of plant anti-cancer drugs. Since the 1980s, the American medical research department has increased, inspired by the herbal develop cooperation with China, the company successfully listed the development of paclitaxel anti-cancer drugs, many U.S. companies have to compete with China plant anti-cancer drug research. Among them, the topology is currently on the market of international anticancer drugs topotecan and irinotecan and other important products.
Martine recent years, China developed a new type of plant anticancer drug belonging to the cancer cells the telomerase inhibitor class. It is reported that oxymatrine has been several manufacturers in China to develop into a new anticancer drug listed. Oxymatrine as the basic raw materials of plant anticancer drug because of side effects is much lower than conventional chemotherapy drugs, sales in the market.
garcinia is also a long history of Chinese herbal medicine is one of the extract from garcinia biflavones class composition in the animal studies showed a strong inhibitory effect on tumor angiogenesis. The researchers are now further pharmacological studies on pairs of flavonoids of garcinia, once through clinical resveratrol trials, the market would give rise to a plant source of new anticancer drugs.
It is understood that there are other developing phytogenic anticarcinogen such as amaryllidaceae extracts, neem sub-extract, oleander leaf extract, artemisinin derivatives (such as dihydroartemisinin, artesunate etc.), annona extract and so on. Because of funds and other factors, there are just a dozen of Chinese medical anticancer drugs. But it is sure that in the future phytogenic anticarcinogen will become a new force in international anticancer drugs market.
Source:http://www.cospcn.com
没有评论:
发表评论